米国の幹細胞治療市場：2008年

Abstract

Though only 2 stem cell products were available in 2007, new stem cell therapy products will begin to enter the market as early as 2009. In the best case scenario, over 30 vendors will enter the stem cell therapy market by 2012, and by 2017, almost 90 vendors will be active in the market.

The US stem cell therapies market includes the use of stem cells to treat orthopedic degenerative disease, cardiovascular disease, diabetes, neurological disease, cancer, retinal disease, aesthetic conditions, and other chronic and autoimmune disorders.

Table of Contents

TABLE OF CONTENTS

LIST OF EXHIBITS

EXECUTIVE SUMMARY

METHODOLOGY

1.0 STEM CELL THERAPIES BACKGROUND

• 1.1 Regenerative Medicine
• 1.2 Stem Cell Sources, Properties, and Types
  • 1.2.1 Types of Germ Layers
  • 1.2.2 Properties of Stem Cells
  • 1.2.3 Sources and Types of Stem Cells
  • 1.2.4 Approaches to Stem Cell Therapy
  • 1.2.5 Stem Cell Dose
  • 1.2.6 Stem Cell Administration
• 1.3 Stem Cell Challenges
  • 1.3.1 History of Stem Cell Research
  • 1.3.2 Ethical Challenges
  • 1.3.3 Political Challenges
  • 1.3.4 Regulatory Challenges
  • 1.3.5 The Promise of Stem Cell Research
• 1.4 Stem Cell Market

2.0 US STEM CELL THERAPIES MARKET

• 2.1 Market Overview
• 2.2 Market Analysis
  • 2.2.1 Procedures
  • 2.2.2 Market Forecast
  • 2.2.3 Market Drivers and Limiters
    • 2.2.3.1 Market Drivers
    • 2.2.3.2 Market Limiters
• 2.3 Competitive Analysis

3.0 ORTHOPEDIC STEM CELL THERAPY MARKET

• 3.1 Market Overview
  • 3.1.1 Relevant Conditions
  • 3.1.2 Existing Therapies
  • 3.1.3 Stem Cell Therapies
• 3.2 Market Analysis
  • 3.2.1 Procedures
  • 3.2.2 Market Forecast
  • 3.2.3 Market Drivers and Limiters
• 3.3 Competitive Analysis

4.0 CARDIOVASCULAR STEM CELL THERAPY MARKET

• 4.1 Market Overview
  • 4.1.1 Relevant Conditions
  • 4.1.2 Existing Therapies
  • 4.1.3 Stem Cell Therapies
• 4.2 Market Analysis
  • 4.2.1 Procedures
  • 4.2.2 Market Forecast
  • 4.2.3 Market Drivers and Limiters
• 4.3 Competitive Analysis

5.0 DIABETES STEM CELL THERAPY MARKET

• 5.1 Market Overview
  • 5.1.1 Relevant Conditions
  • 5.1.2 Existing Therapies
  • 5.1.3 Stem Cell Therapies
• 5.2 Market Analysis
  • 5.2.1 Procedures
  • 5.2.2 Market Forecast
  • 5.2.3 Market Drivers and Limiters
• 5.3 Competitive Analysis

6.0 NEUROLOGICAL STEM CELL THERAPY MARKET

• 6.1 Market Overview
  • 6.1.1 Relevant Conditions
  • 6.1.2 Existing Therapies
  • 6.1.3 Stem Cell Therapies
• 6.2 Market Analysis
  • 6.2.1 Procedures
  • 6.2.2 Market Forecast
  • 6.2.3 Market Drivers and Limiters
• 6.3 Competitive Analysis

7.0 TISSUE AND ORGAN STEM CELL THERAPY MARKET

• 7.1 Market Overview
  • 7.1.1 Relevant Conditions
  • 7.1.2 Existing Therapies
  • 7.1.3 Stem Cell Therapies
• 7.2 Market Analysis
• 7.3 Competitive Analysis

8.0 COMPANY PROFILES

• 8.1 Aastrom Biosciences
• 8.2 Advanced Cell Technologies
• 8.3 Arteriocyte
• 8.4 Blackstone Medical
• 8.5 Cytori Therapeutics
• 8.6 Geron
• 8.7 Harvest Technologies
• 8.8 International Stem Cell Corporation
• 8.9 Osiris Therapeutics

List of Exhibits

EXECUTIVE SUMMARY

• Exhibit 1: Number of Stem Cell Therapy Products, US, 2007-2017
• Exhibit 2: Number of Orthopedic Stem Cell Therapy Products, US, 2007-2017
• Exhibit 3: Number of Cardiovascular Stem Cell Therapy Products, US, 2007-2017
• Exhibit 4: Number of Diabetes Stem Cell Therapy Products, US, 2007-2017
• Exhibit 5: Number of Neurological Stem Cell Therapy Products, US, 2007-2017
• Exhibit 6: Number of Tissue and Organ Stem Cell Therapy Products, US, 2007-2017

METHODOLOGY

CHAPTER 1: STEM CELL THERAPIES BACKGROUND

• Exhibit 7: The Differentiation Potential of Stem Cells
• Exhibit 8: The Ectoderm, Mesoderm and Endoderm Germ Layers
• Exhibit 9: The Balance of Stem Cell Self‐Renewal and Differentiation
• Exhibit 10: Cell Types Involved in Stem Cell Therapies
• Exhibit 11: Comparison of Types of Stem Cells
• Exhibit 12: Sources of Adult Stem Cells
• Exhibit 13: The US FDA Approval Process for Biopharmaceuticals

CHAPTER 2: US STEM CELL THERAPIES MARKET

• Exhibit 14: Number of Stem Cell Products in the Stem Cell Therapy Market, US, 2006-2017 (Graphical Format)
• Exhibit 15: Number of Stem Cell Products in the Stem Cell Therapy Market, US, 2006-2017 (Tabular Format)
• Exhibit 16: Drivers and Limiters of the Stem Cell Therapy Market, US
• Exhibit 17: Selected Companies in the Stem Cell Market, by Segment, US, 2007
• Exhibit 18: Selected Companies in the Stem Cell Market, by Technology. US, 2007
• Exhibit 19: Selected Companies in the Stem Cell Market, by Stem Cell Type
• Exhibit 20: Selected Companies in the Stem Cell Market, US, 2007

CHAPTER 3: ORTHOPEDIC STEM CELL THERAPY MARKET

• Exhibit 21: Orthopedic Stem Cell Therapy Market, US (US$) 2006?2012
• Exhibit 22: Number of Stem Cell Products in the Orthopedic Stem Cell Therapy Market, US, 2006-2017 (Graphical Format)
• Exhibit 23: Orthopedic Stem Cell Therapy Procedures, US, 2006?2012
• Exhibit 24: Total Orthopedic Incidence and Orthopedic Stem Cell Therapy Procedures, US, 2006-2017 (Graphical Format)
• Exhibit 25: Total Orthopedic Incidence and Orthopedic Stem Cell Therapy Procedures, US, 2006-2017 (Tabular Format)
• Exhibit 26: Number of Stem Cell Products in the Orthopedic Stem Cell Therapy Market, US, 2006-2017 (Tabular Format)
• Exhibit 27: Orthopedic Stem Cell Therapy Market, US (US$), 2006?2012 (Tabular Format)
• Exhibit 28: Drivers of the Orthopedic Stem Cell Therapy Market, US
• Exhibit 29: Limiters of the Orthopedic Stem Cell Therapy Market, US
• Exhibit 30: Selected Companies Offering and/or Developing Products in the Orthopedic Stem Cell Therapy Market, 2007

CHAPTER 4: CARDIOVASCULAR STEM CELL THERAPY MARKET

• Exhibit 31: Number of Stem Cell Products in the Cardiovascular Stem Cell Therapy Market, US, 2006-2017 (Graphical Format)
• Exhibit 32: Total Cardiovascular Procedures and Cardiovascular Stem Cell Therapy Procedures (Optimistic Scenario), US, 2006-2017 (Graphical Format)
• Exhibit 33: Total Cardiovascular Procedures and Cardiovascular Stem Cell Therapy Procedures (Optimistic Scenario), US, 2006-2017 (Tabular Format)
• Exhibit 34: Total Cardiovascular Procedures and Cardiovascular Stem Cell Therapy Procedures (Pessimistic Scenario), US, 2006-2017 (Graphical Format)
• Exhibit 35: Total Cardiovascular Procedures and Cardiovascular Stem Cell Therapy Procedures (Pessimistic Scenario), US, 2006-2017 (Tabular Format)
• Exhibit 36: Number of Stem Cell Products in the Cardiovascular Stem Cell Therapy Market, US, 2006-2017 (Tabular Format)
• Exhibit 37: Drivers of the Cardiovascular Stem Cell Therapy Market, US
• Exhibit 38: Limiters of the Cardiovascular Stem Cell Therapy Market, US
• Exhibit 39: Selected Companies Developing Products in the Cardiovascular Stem Cell Therapy Market, 2007

CHAPTER 5: DIABETES STEM CELL THERAPY MARKET

• Exhibit 40: Number of Stem Cell Products in the Diabetes Stem Cell Therapy Market, US, 2006-2017 (Graphical Format)
• Exhibit 41: Total Diabetes Procedures and Diabetes Stem Cell Therapy Procedures (Optimistic Scenario), US, 2006-2017 (Graphical Format)
• Exhibit 42: Total Diabetes Procedures and Diabetes Stem Cell Therapy Procedures (Optimistic Scenario), US, 2006-2017 (Tabular Format)
• Exhibit 43: Total Diabetes Procedures and Diabetes Stem Cell Therapy Procedures (Pessimistic Scenario), US, 2006-2017 (Graphical Format)
• Exhibit 44: Total Diabetes Procedures and Diabetes Stem Cell Therapy Procedures (Pessimistic Scenario), US, 2006-2017 (Tabular Format)
• Exhibit 45: Number of Stem Cell Products in the Diabetes Stem Cell Therapy Market, US, 2006-2017 (Tabular Format)
• Exhibit 46: Drivers of the Diabetes Stem Cell Therapy Market, US
• Exhibit 47: Limiters of the Diabetes Stem Cell Therapy Market, US
• Exhibit 48: Selected Companies Developing Products in the Diabetes Stem Cell Therapy Market, 2007

CHAPTER 6: NEUROLOGICAL STEM CELL THERAPY MARKET

• Exhibit 49: Number of Stem Cell Products in the Neurological Stem Cell Therapy Market, US, 2006-2017 (Graphical Format)
• Exhibit 50: Total Neurological Procedures and Neurological Stem Cell Therapy Procedures (Optimistic Scenario), US, 2006-2017 (Graphical Format)
• Exhibit 51: Total Neurological Procedures and Neurological Stem Cell Therapy Procedures (Optimistic Scenario), US, 2006-2017 (Tabular Format)
• Exhibit 52: Total Neurological Procedures and Neurological Stem Cell Therapy Procedures (Pessimistic Scenario), US, 2006-2017 (Graphical Format)
• Exhibit 53: Total Neurological Procedures and Neurological Stem Cell Therapy Procedures (Pessimistic Scenario), US, 2006-2017 (Tabular Format)
• Exhibit 54: Number of Stem Cell Products in the Neurological Stem Cell Therapy Market, US, 2006-2017 (Tabular Format)
• Exhibit 55: Drivers of the Neurological Stem Cell Therapy Market, US
• Exhibit 56: Limiters of the Neurological Stem Cell Therapy Market, US
• Exhibit 57: Selected Companies Developing Products in the Neurological Stem Cell Therapy Market, US, 2007

CHAPTER 7: TISSUE AND ORGAN STEM CELL THERAPY MARKET

• Exhibit 58: Number of Stem Cell Products in the Tissue and Organ Stem Cell Therapy Market, US, 2006-2017 (Graphical Format)
• Exhibit 59: Number of Stem Cell Products in the Tissue and Organ Stem Cell Therapy Market, US, 2006-2017 (Tabular Format)
• Exhibit 60: Selected Companies Developing Products in the Tissue and Organ Stem Cell Therapy Market, US, 2007

CHAPTER 8: COMPANY PROFILES